Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Bifurcation Disease. What Do We Know, What Should We Do?
JACC: Cardiovascular Interventions, Volume 1, No. 3, Year 2008
Notification
URL copied to clipboard!
Description
The percutaneous treatment of coronary bifurcations has moved past an important milestone in that the 1- versus 2-stent debate appears to have been resolved. The provisional approach of implanting one stent on the main branch should be the default approach in most bifurcations lesions. Selection of the most appropriate strategy for an individual bifurcation is important. Some bifurcations require 1 stent, whereas others require the stenting of both branches. Irrespective of whether a 1- or 2-stent strategy is chosen, the results after bifurcation percutaneous coronary intervention (PCI) have dramatically improved. Dedicated bifurcation stents are an exciting new technology that may further simplify the management of bifurcation PCI and change some of these concepts. © 2008 American College of Cardiology Foundation.
Authors & Co-Authors
Latib, Azeem M.
Italy, Milan
Irccs Ospedale San Raffaele
South Africa, Cape Town
University of Cape Town
Colombo, Antonio
Italy, Milan
Irccs Ospedale San Raffaele
Italy, Milan
Emo Centro Cuore Columbus
Statistics
Citations: 261
Authors: 2
Affiliations: 3
Identifiers
Doi:
10.1016/j.jcin.2007.12.008
ISSN:
19368798
Study Design
Randomised Control Trial